Detalles de la búsqueda
1.
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
Blood
; 135(7): 491-504, 2020 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31805182
2.
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
N Engl J Med
; 377(16): 1513-1524, 2017 10 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-28844193
3.
Comparison of Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Multicriteria Decision Analysis.
Value Health
; 20(10): 1394-1402, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29241899
4.
A single-dose, randomized, double-blind, double dummy, placebo and positive-controlled, five-way cross-over study to assess the pharmacodynamic effects of lorediplon in a phase advance model of insomnia in healthy Caucasian adult male subjects.
Hum Psychopharmacol
; 29(3): 266-73, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24911577
5.
Safety and tolerability of spesolimab in patients with ulcerative colitis.
Expert Opin Drug Saf
; 22(2): 141-152, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35861588
6.
Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials.
Thromb Haemost
; 122(9): 1573-1583, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35909257
7.
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism.
J Thromb Haemost
; 19(5): 1259-1270, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33636042
8.
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Lancet Haematol
; 8(1): e22-e33, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33290737
9.
Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials.
Thromb Haemost
; 118(9): 1625-1636, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30112751
10.
Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.
Res Pract Thromb Haemost
; 2(1): 69-76, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30046708
11.
Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism.
Res Pract Thromb Haemost
; 2(2): 347-356, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30046738
12.
Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design.
Res Pract Thromb Haemost
; 2(3): 580-590, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30046763
13.
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
Thromb Haemost
; 117(11): 2168-2175, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29202215
14.
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
Clin Cardiol
; 39(10): 555-564, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27565018
15.
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.
Eur J Heart Fail
; 18(5): 482-9, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27071916
16.
In vitro percutaneous absorption and metabolism of ozenoxacin in excised human skin.
Future Microbiol
; 9(8 Suppl): S3-9, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25209522
17.
Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers.
Future Microbiol
; 9(8 Suppl): S11-6, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25209519
18.
Skin tissue exposure of once- versus twice-daily topical ozenoxacin 2% cream: a Phase I study in healthy volunteers.
Future Microbiol
; 9(8 Suppl): S17-22, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25209520
19.
Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo.
Future Microbiol
; 9(8 Suppl): S33-40, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25209523
20.
Cumulative irritation, sensitizing potential, phototoxicity and photoallergy of ozenoxacin in healthy adult volunteers.
Future Microbiol
; 9(8 Suppl): S23-31, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25209521